Literature DB >> 16598738

The distribution of serum prostate-specific antigen levels among American men: implications for prostate cancer prevalence and screening.

Michael P Porter1, Janet L Stanford, Paul H Lange.   

Abstract

BACKGROUND: The purpose of this study was to describe the distribution of serum prostate-specific antigen (PSA) among American men and to estimate the number of prevalent cases of biopsy detectable prostate cancer among men with normal serum PSA.
METHODS: We analyzed data of the National Health and Nutrition Examination Survey 2001-2002 (NHANES 2001-2002) data and combined these results with published data from the Prostate Cancer Prevention Trial (PCPT).
RESULTS: Most men in the US have a serum PSA < or = 4.0 ng/ml, and mean and median serum PSA values rise steadily with age. There are an estimated 1,607,585 (95% CI 1,370,848-1,844,322) prevalent cases of biopsy detectable prostate cancer in men aged 62-85 years with a serum PSA < or = 4 ng/ml. Among men aged 62-75 years, there are an estimated 1,252,143 (95% CI 1,054,677-1,449,609) prevalent cases, including an estimated 195,499 (95% CI 140,234-250,764) high-grade tumors.
CONCLUSION: A large number of prevalent cases of biopsy detectable prostate cancer exist in American men with a normal PSA. Copyright 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598738     DOI: 10.1002/pros.20417

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  5 in total

1.  Distribution of PSA velocity by total PSA levels: data from the Baltimore Longitudinal Study of Aging.

Authors:  Stacy Loeb; H Ballentine Carter; Edward M Schaeffer; Anna Kettermann; Luigi Ferrucci; E Jeffrey Metter
Journal:  Urology       Date:  2011-01       Impact factor: 2.649

2.  Association of urinary phytoestrogen concentrations with serum concentrations of prostate-specific antigen in the National Health and Nutrition Examination Survey.

Authors:  Esther Walser-Domjan; Aline Richard; Monika Eichholzer; Elizabeth A Platz; Jakob Linseisen; Sabine Rohrmann
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

3.  Prognostic value of ERG oncoprotein in prostate cancer recurrence and cause-specific mortality.

Authors:  E Sophie Spencer; Richard B Johnston; Ryan R Gordon; Jared M Lucas; Cigdem Himmetoglu Ussakli; Antonio Hurtado-Coll; Shiv Srivastava; Peter S Nelson; Christopher R Porter
Journal:  Prostate       Date:  2013-01-17       Impact factor: 4.104

4.  A Review on the Clinical Utility of PSA in Cancer Prostate.

Authors:  Mohan Adhyam; Anish Kumar Gupta
Journal:  Indian J Surg Oncol       Date:  2012-03-03

5.  Can prostate specific antigen velocity thresholds decrease insignificant prostate cancer detection?

Authors:  Stacy Loeb; Kimberly A Roehl; Brian T Helfand; Donghui Kan; William J Catalona
Journal:  J Urol       Date:  2010-01       Impact factor: 7.450

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.